The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

(HealthDay News) — The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.

After patients had undergone a 3-week run-in of subcutaneous darbepoetin alfa, they were randomized 1:1 to receive either subcutaneous or intravenous darbepoetin alfa once a week for 20 weeks ...

Pope Francis is eating and intravenous feeding has never been mentioned, the Vatican said as he continues to battle pneumonia ...

Researchers from Revolo Biotherapeutics Ltd. recently presented preclinical data for IRL-201104, a clinical-stage ...

The following is a summary of “Discarded intravenous medication in the ICU: the GAME-OVER multicenter prospective observational study,” published in the February 2025 issue of Critical Care by ...

The global IV therapy and vein access devices market is on a trajectory of significant growth, projected to expand from USD 28.7 billion in 2024 to an estimated USD 47.3 billion by 2034. With a ...

Switching from established intravenous (IV) therapy to subcutaneous infliximab was associated with high treatment persistence, stable clinical disease activity, and consistent faecal calprotectin ...

our study was limited by low power to detect an effect in a small but clinically important fraction of patients receiving the combination of high-dose intravenous calcium and concurrent ceftriaxone.

Scientists at the Icahn School of Medicine at Mount Sinai have developed a lipid nanoparticle system capable of delivering messenger RNA (mRNA) to the brain via intravenous injection, a challenge ...